Advances in targeted drug therapy for relapse/refractory diffuse large B-cell lymphoma

VernacularTitle:复发难治性弥漫大B细胞淋巴瘤靶向药物治疗进展
Author: Liyan LI ¹ ; Rong FU
Author Information

1. 天津医科大学总医院血液内科(天津市300052
Keywords: diffuse large B-cell lymphoma (DLBCL); relapse; refractory; targeted therapy
From: Chinese Journal of Clinical Oncology 2019;46(11):581-585
CountryChina
Language:Chinese
Abstract: Lymphoma is a group of heterogeneous hematological malignant tumors originating from lymph nodes or other lymphoid tissues, including Hodgkin's lymphoma and non-Hodgkin's lymphoma. Diffuse large B-cell lymphoma (DLBCL) is one of the most com-mon subtypes of non-Hodgkin's lymphoma (NHL) with obvious heterogeneity. Standard R-CHOP regimen (rituximab combined with cy-clophosphamide, adriamycin, vincristine and prednisone) can significantly improve the survival of more than 60% of patients. Howev-er, there are still about 30%-40% of patients with relapse or refractory disease, and the prognosis is very poor. How to prolong the sur-vival of relapsed/refractory DLBCL patients and improve their prognosis has become a research hotspot. With the continuous in-depth study of gene expression profiles and molecular mechanisms of drug resistance, new chemotherapy schemes and new drugs emerge, which brings new hope for individualized precise treatment of relapsed/refractory DLBCL. This article reviews the recent progress of targeted drugs in the treatment of relapsed/refractory DLBCL.